Carolina Leticia Bellera

Prof. Dr. Carolina Leticia Bellera

orcid
LIDeB | UNLP | CONICET

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
ATAlan Talevi
Alan Talevi
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
(2019). Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opinion on Drug Discovery. Ahead of Print.

1 March 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
DBDarío E. Balcazar
Darío E. Balcazar
MVM. Cristina Vanrell
M. Cristina Vanrell
ACA. Florencia Casassa
A. Florencia Casassa
PPPablo H. Palestro
Pablo H. Palestro
ATAlan Talevi
Alan Talevi

27 July 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
MLManuel A. Llanos
Manuel A. Llanos
MGMelisa Edith Gantner
Melisa Edith Gantner
SRSantiago Rodriguez
Santiago Rodriguez
LALucas N. Alberca
Lucas N. Alberca
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
LGLuciana Gavernet
Luciana Gavernet

1 June 2007 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
PDPablo R. Duchowicz
Pablo R. Duchowicz
ATAlan Talevi
Alan Talevi
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
LBLuis E. Bruno-Blanch
Luis E. Bruno-Blanch
ECEduardo A. Castro
Eduardo A. Castro

1 January 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ATAlan Talevi
Alan Talevi
MGMohammad Goodarzi
Mohammad Goodarzi
EOErlinda V. Ortiz
Erlinda V. Ortiz
PDPablo R. Duchowicz
Pablo R. Duchowicz
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
LBLuis E. Bruno-Blanch
Luis E. Bruno-Blanch

1 July 2012 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
ATAlan Talevi
Alan Talevi
Carolina Leticia BelleraCarolina Leticia Bellera
Carolina Leticia Bellera
MIMauricio Di Ianni
Mauricio Di Ianni
PDPablo R. Duchowicz
Pablo R. Duchowicz
LBLuis E. Bruno-Blanch
Luis E. Bruno-Blanch
ECEduardo A. Castro
Eduardo A. Castro
We describe the opportunities posed by computer-assisted drug design in the light of two aspects of the current drug discovery scenario: the decline of innovation due to high attrition rates at clinical stage of development and the combinatorial explosion emerging from exponential growth of feasible small molecules and genome and proteome exploration. We present an overview of recent reports from our group in the field of rational drug development, by using topological descriptors (either alone, or in combination with different 3D approaches) and a diversity of modeling techniques such as Linear Discriminant Analysis and the Replacement Method. Modeling efforts aimed at the integrated prediction of several significant molecular properties in the field of drug discovery, such as pharmacological activity, aqueous solubility, human intestinal permeability and affinity to P-glycoprotein (ABCB1, MDR1) are reviewed. The suitability of conformation-independent descriptors to explore large chemical repositories is highlighted, as well as the opportunities posed by in silico guided drug repurposing.